---
title: "ABVC BioPharma Shareholders Back Board, Equity Plan Changes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280845212.md"
description: "ABVC BioPharma Shareholders Back Board, Equity Plan Changes"
datetime: "2026-03-27T20:47:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280845212.md)
  - [en](https://longbridge.com/en/news/280845212.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280845212.md)
---

# ABVC BioPharma Shareholders Back Board, Equity Plan Changes

ABVC BioPharma Shareholders Back Board, Equity Plan Changes

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ABVC.US](https://longbridge.com/en/quote/ABVC.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Insulet Shareholders Approve Proposals at Annual Meeting](https://longbridge.com/en/news/287276112.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients](https://longbridge.com/en/news/287144318.md)
- [Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK-positive NSCLC at ASCO 2026](https://longbridge.com/en/news/287275055.md)
- [Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC](https://longbridge.com/en/news/287274011.md)